Sugi Predict

Sugi Predict / Targets / PLA2G2D

PLA2G2D

Group IID secretory phospholipase A2 · Q9UNK4 · PLA2G2D on Sugi Atlas →

4,642 patent compounds predicted against PLA2G2D, 3,134 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL818585 SCHEMBL818585 0.85 5/20
Varespladib Varespladib (SCHEMBL1232548) 0.83 5/20
Varespladib Varespladib (SCHEMBL26726) 1.00 4/20
Varespladib Methyl Varespladib Methyl (SCHEMBL25678) 0.83 4/20
SCHEMBL2157246 SCHEMBL2157246 0.76 4/20
SCHEMBL3198502 SCHEMBL3198502 0.72 4/20
SCHEMBL818717 SCHEMBL818717 0.70 4/20
SCHEMBL2157520 SCHEMBL2157520 0.70 4/20
SCHEMBL2157063 SCHEMBL2157063 0.68 4/20
SCHEMBL820017 SCHEMBL820017 0.66 4/20
SCHEMBL2156877 SCHEMBL2156877 0.65 4/20
SCHEMBL2157074 SCHEMBL2157074 0.64 4/20
SCHEMBL2157038 SCHEMBL2157038 0.64 4/20
SCHEMBL2164905 SCHEMBL2164905 0.62 4/20
SCHEMBL819235 SCHEMBL819235 0.59 4/20
SCHEMBL3198216 SCHEMBL3198216 0.59 4/20
SCHEMBL818386 SCHEMBL818386 0.52 4/20
SCHEMBL818498 SCHEMBL818498 0.79 3/20
SCHEMBL4652248 SCHEMBL4652248 0.66 3/20
SCHEMBL2595689 SCHEMBL2595689 0.63 3/20

Clinical trials — most relevant to PLA2G2D by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparative Assessment of Preoperative Versus Postoperative Submucosal Dexamethasone on Postoperative Complications Following Surgical Extraction of Mandibular Third Molar: Randomized Controlled Trial PHASE4NOT_YET_RECRUITING
Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL) PHASE4COMPLETED
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis PHASE3COMPLETED
European Celecoxib Trial in Primary Breast Cancer PHASE3COMPLETED
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes PHASE3UNKNOWN
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM PHASE3COMPLETED
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study PHASE2/PHASE3RECRUITING
Lovaza's Effect on the Activation of Platelets PHASE2COMPLETED
Belimumab With Rituximab for Primary Membranous Nephropathy PHASE2RECRUITING
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies PHASE2COMPLETED
Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke nanCOMPLETED
PET Imaging of DHA Metabolism nanCOMPLETED
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates nanRECRUITING
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes nanCOMPLETED
Mucomyst for Hepatitis C nanSUSPENDED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy nanCOMPLETED
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
Role of PLA2G1B During HIV Infection nanUNKNOWN
Positron Emission Tomography (PET) to Study Brain Signaling nanCOMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer nanCOMPLETED
Investigation of Lipoxin A4, Annexin A1 and Interleukin-1 Beta Levels in Individuals With Periodontitis. nanCOMPLETED
An Outcome Analysis of Primary Membranous Nephropathy nanRECRUITING
Lp-PLA2 and Coronary Atherosclerosis in Humans nanCOMPLETED
Autotaxin (ATX) as a Marker for Breast Cancer nanUNKNOWN
Rituximab, Cyclophosphamide, and Corticosteroids in Primary Membranous Nephropathy nanUNKNOWN
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation nanCOMPLETED
Immune System Related Kidney Disease nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PLA2G2D binder may also engage these)

ProteinNameSimilarity
Q9WVF6 — 1.000 Q9WVF6 →
P47711 — 0.998 P47711 →
P97391 — 0.997 P97391 →
Q2YHJ7 — 0.996 Q2YHJ7 →
Q90W39 — 0.996 Q90W39 →
Q56JZ2 — 0.996 Q56JZ2 →
P20474 — 0.995 P20474 →
Q6EER4 — 0.995 Q6EER4 →
Q2YHJ2 — 0.995 Q2YHJ2 →
PLA2G2E Group IIE secretory phospholipase A2 0.995 landscape →
P24027 — 0.994 P24027 →
Q71QE8 — 0.994 Q71QE8 →
P49121 — 0.994 P49121 →
A8CG90 — 0.993 A8CG90 →
A8E2V8 — 0.993 A8E2V8 →
Q910A0 — 0.993 Q910A0 →
P86974 — 0.993 P86974 →
Q6H3C9 — 0.993 Q6H3C9 →
P0DJN7 — 0.993 P0DJN7 →
Q7ZTA8 — 0.992 Q7ZTA8 →
Q8JIY9 — 0.992 Q8JIY9 →
Q2PG83 — 0.992 Q2PG83 →
G3DT18 — 0.992 G3DT18 →
P31482 — 0.992 P31482 →
P14423 — 0.992 P14423 →
Q6H3C7 — 0.992 Q6H3C7 →
Q1ZY03 — 0.992 Q1ZY03 →
Q7ZTA7 — 0.992 Q7ZTA7 →
Q6EAN6 — 0.991 Q6EAN6 →
Q9QUL3 — 0.991 Q9QUL3 →